Legend Biotech Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $66.54
- Today's High:
- $70
- Open Price:
- $69.99
- 52W Low:
- $37.3
- 52W High:
- $77.32
- Prev. Close:
- $70.11
- Volume:
- 453773
Company Statistics
- Market Cap.:
- $13.05 billion
- Book Value:
- 7.758
- Revenue TTM:
- $164.66 million
- Operating Margin TTM:
- -304.83%
- Gross Profit TTM:
- $-284006000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.24%
- Return on Equity TTM:
- -54.03%
Company Profile
Legend Biotech Corp had its IPO on 2020-06-05 under the ticker symbol LEGN.
The company operates in the Healthcare sector and Biotechnology industry. Legend Biotech Corp has a staff strength of 1,576 employees.
Stock update
Shares of Legend Biotech Corp opened at $69.99 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $66.54 - $70, and closed at $66.63.
This is a -4.96% slip from the previous day's closing price.
A total volume of 453,773 shares were traded at the close of the day’s session.
In the last one week, shares of Legend Biotech Corp have slipped by -6.93%.
Legend Biotech Corp's Key Ratios
Legend Biotech Corp has a market cap of $13.05 billion, indicating a price to book ratio of 19.803 and a price to sales ratio of 73.1773.
In the last 12-months Legend Biotech Corp’s revenue was $164.66 million with a gross profit of $-284006000 and an EBITDA of $-491214016. The EBITDA ratio measures Legend Biotech Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Legend Biotech Corp’s operating margin was -304.83% while its return on assets stood at -21.24% with a return of equity of -54.03%.
In Q2, Legend Biotech Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 512.6%.
Legend Biotech Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Legend Biotech Corp’s profitability.
Legend Biotech Corp stock is trading at a EV to sales ratio of 68.6081 and a EV to EBITDA ratio of -24.2839. Its price to sales ratio in the trailing 12-months stood at 73.1773.
Legend Biotech Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.93 billion
- Total Liabilities
- $201.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Legend Biotech Corp ended 2024 with $1.93 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.93 billion while shareholder equity stood at $1.41 billion.
Legend Biotech Corp ended 2024 with $0 in deferred long-term liabilities, $201.38 million in other current liabilities, 36000.00 in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $1.23 billion and cash and short-term investments were $1.51 billion. The company’s total short-term debt was $3,558,000 while long-term debt stood at $270.61 million.
Legend Biotech Corp’s total current assets stands at $1.61 billion while long-term investments were $4.21 million and short-term investments were $281.57 million. Its net receivables were $62.90 million compared to accounts payable of $21.54 million and inventory worth $15.20 million.
In 2024, Legend Biotech Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Legend Biotech Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $66.63
- 52-Week High
- $77.32
- 52-Week Low
- $37.3
- Analyst Target Price
- $88.18
Legend Biotech Corp stock is currently trading at $66.63 per share. It touched a 52-week high of $77.32 and a 52-week low of $77.32. Analysts tracking the stock have a 12-month average target price of $88.18.
Its 50-day moving average was $70.51 and 200-day moving average was $59.64 The short ratio stood at 9.73 indicating a short percent outstanding of 0%.
Around 137% of the company’s stock are held by insiders while 4087.9% are held by institutions.
Frequently Asked Questions About Legend Biotech Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.